Investigational drug · Phase 2
AB-101
Also called: zabalafin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "AB-101"
First trial start
2021
Mar 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AB-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis (Eczema)
- Atopic Dermatitis Eczema
- Atopic Dermatitis
- Atopic Dermatitis (AD)
- Eczema
- Eczema, Atopic
- Non Hodgkin Lymphoma
Approved drugs for the same conditions: Hodgkin lymphoma · Atopic dermatitis (eczema) · Hematology and blood cancers · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "AB-101" as an intervention, largest first.
- Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.Pivotal-lookingCompleted
Arbutus Biopharma CorporationIndustry
NCT05960240 · 128 participants · Start Aug 30, 2023 · Primary completion Dec 4, 2025
Drug: AB-101; Placebo and 1 more · For: Chronic Hepatitis b
Sites: Hong Kong, Hong Kong; Bergamo, Italy; Milan, Italy · 10 sites in all
Alphyn BiologicsIndustry
NCT06855745 · 72 participants (planned) · Start Mar 25, 2025 · Primary completion Oct 30, 2025
Drug: zabalafin · For: Atopic Dermatitis (Eczema); Atopic Dermatitis Eczema; Atopic Dermatitis and 3 more
Sites: Brookvale, Australia; Darlinghurst, Australia; Kogarah, Australia · 12 sites in all
- AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusActive, not recruiting
Artiva Biotherapeutics, Inc.Industry
NCT06265220 · 51 participants (planned) · Start Apr 3, 2024 · Primary completion Aug 2027
Drug: AB-101; Cyclophosphamide and 3 more · For: Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 9 sites in all
Artiva Biotherapeutics, Inc.Industry
NCT04673617 · 45 participants · Start Mar 29, 2021 · Primary completion Oct 6, 2025
Drug: AB-101; Rituximab and 4 more · For: Non Hodgkin Lymphoma
Sites: Birmingham, Alabama; Tucson, Arizona; Orange, California · 21 sites in all
IRIS Research and Development, LLCAcademic, hospital or other
NCT06581562 · 30 participants (planned) · Start May 15, 2024 · Primary completion Jul 2027
Drug: AB-101; Rituximab and 2 more · For: Rheumatoid Arthritis; Pemphigus Vulgaris; Granulomatosis With Polyangiitis and 1 more
Sites: Plantation, Florida
Affimed GmbHIndustry
NCT05883449 · 25 participants · Start Oct 10, 2023 · Primary completion Nov 7, 2024
Drug: AFM13; AB-101 and 3 more · For: Relapsed or Refractory Hodgkin Lymphoma; Peripheral T Cell Lymphoma
Sites: Birmingham, Alabama; Duarte, California; Orange, California · 15 sites in all
Applied Biology, Inc.Industry
NCT03592121 · 3 participants · Start Jul 9, 2018 · Primary completion Oct 12, 2019
Drug: AB-101; Placebo · For: Sexual Dysfunction; Sexual Arousal Disorder; Sexual Dysfunction, Physiological and 4 more
Sites: Newport Beach, California
Newest research
PubMed records naming it or its code names, newest first.
- The Essential Role of Topical Targeted Therapy in Atopic Dermatitis.
Lio P, Benjamin L, Gonzalez ME, et al. · J Drugs Dermatol 2026
- High affinity CD16v/v allogeneic NK cell therapy, AB-101, enhances antibody-mediated cytotoxicity in B-cell driven diseases.
Guerrettaz L, Rogers P, Chu G, et al. · Cytotherapy 2026
- The Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option.
Schachner LA, Hebert AA, Silverberg N, et al. · J Drugs Dermatol 2025
- Practical Algorithm on Topical Treatment of Flaring Atopic Dermatitis (AD) With or Without Secondary Infection.
Schachner LA, Hebert AA, Sidbury R, et al. · J Drugs Dermatol 2025
- Effect of the plant probiotic bacteria on terpenoid indole alkaloid biosynthesis pathway gene expression profiling, vinblastine and vincristine content in the root of Catharanthus roseus.
Ahmadzadeh M, Keshtkar AH, Moslemkhany K, et al. · Mol Biol Rep 2022
- Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.
Zheng J, Vasselli JR, King JF, et al. · Am J Ther 2016
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.